Sarepta gene therapy sales drop despite beating estimates

Elevidys sales fell but cleared low bar

Sarepta's stock dropped after reporting continued sales declines for Elevidys, its Duchenne muscular dystrophy gene therapy, despite beating Wall Street expectations (per BioPharma Dive). The company's shares tumbled as the market focused on the underlying sales trajectory rather than the modest earnings beat.

Analysts noted that investor attention is shifting toward Sarepta's early-stage RNA drug candidates rather than the struggling gene therapy launch. This suggests the market has largely written off Elevidys as a commercial disappointment.

Gene therapy launch struggles continue

Elevidys represents one of the highest-profile gene therapy launches in recent years, making its commercial difficulties a bellwether for the broader sector. The therapy's inability to gain commercial traction despite addressing a serious rare disease highlights persistent market access challenges for ultra-expensive genetic medicines.

The shift in analyst focus to earlier-stage RNA assets indicates that even positive earnings surprises cannot overcome fundamental concerns about a product's commercial viability. This pattern suggests investors are becoming more skeptical of gene therapy revenue projections across the industry.

Watch for sector-wide impact

Sarepta's experience with Elevidys provides a real-world case study in gene therapy commercialization challenges. Other companies with similar ultra-high-cost genetic medicines should examine Sarepta's market access barriers and pricing strategies to avoid similar outcomes.

The market's quick pivot to focus on earlier-stage assets demonstrates how rapidly investor sentiment can shift when launched products underperform. Companies in the gene therapy space need stronger commercial execution plans before reaching market.